公开(公告)号：US09717783B2

公开(公告)日：2017-08-01

申请号：US13946562

申请日：2013-07-19

Applicant: STC.UNM

Inventor： Bryce Chackerian ,  David S. Peabody ,  Ebenezer Tumban

IPC: A61K39/12 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K2039/5258 ,  A61K2039/58 ,  C12N2710/20034 ,  C12N2795/18023 ,  C12N2795/18071

Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.

公开(公告)号：US10821167B2

公开(公告)日：2020-11-03

申请号：US16074886

申请日：2017-02-01

Applicant: STC.UNM

Inventor： Pamela Hall ,  Bryce Chackerian ,  David S. Peabody ,  Seth Michael Daly ,  Bradley Owen Elmore ,  Kathleen Triplett

IPC: C12Q1/68 ,  A61K39/085 ,  A61P37/04 ,  A61P31/04 ,  A61K39/00

Abstract: The present invention is directed to virus-like particles (VLPs) which are engineered to present epitopes from Staphylococcus aureus (SA), preferably autoinducing peptides (AIPs) which regulate quorum-sensing dependent virulence in this pathogen, or epitopes from SA toxins and leukocidins. These VLPs may be used to provide immunogenic compositions and efficacious vaccines. In a mouse model of SA dermonecrosis, vaccination with AIP-containing VLPs or SA toxin-containing VLPs induces protective immunity to limit the pathogenesis of SA infection and promote bacterial clearance.

公开(公告)号：US09943580B2

公开(公告)日：2018-04-17

申请号：US15023653

申请日：2014-09-11

Applicant: STC.UNM ,  LEIDOS, INC

Inventor： David S. Peabody ,  Bryce Chackerian ,  James Pannucci ,  Gabriel M. Gutierrez ,  Amy Rene Noe ,  Scott Budd Winram ,  Steve Chienwen Huang

IPC: A61K39/39 ,  A61K39/015 ,  C12N7/00 ,  C12N15/10 ,  A61K39/00 ,  A61K35/76

CPC classification number: A61K39/015 ,  A61K35/76 ,  A61K39/39 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/55566 ,  C07K2319/40 ,  C12N7/00 ,  C12N15/1037 ,  C12N2795/18122 ,  C12N2795/18123 ,  C12N2795/18134 ,  Y02A50/412

Abstract: Embodiments are directed to malaria vaccines comprising a bacteriophage VLP displaying a heterologous peptide identified by affinity selection as an anti-malaria mimotope.

公开(公告)号：US20190134170A1

公开(公告)日：2019-05-09

申请号：US16250514

申请日：2019-01-17

Applicant: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. HEALTH AND HUMAN SERVICES ,  STC.UNM

Inventor： Alan Remaley ,  John T. Schiller ,  Marcelo Amar ,  Bryce Chackerian

IPC: A61K39/00 ,  C07K11/00 ,  A61P9/10 ,  A61K38/10 ,  C12N9/64 ,  A61K45/06 ,  A61K47/69

Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.

公开(公告)号：US20170096456A1

公开(公告)日：2017-04-06

申请号：US15358786

申请日：2016-11-22

Applicant: STC.UNM

Inventor： Bryce Chackerian ,  David S. Peabody

IPC: C07K14/005 ,  C12N7/00 ,  A61K39/12

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K47/6901 ,  A61K2039/5258 ,  A61K2039/55566 ,  C12N7/00 ,  C12N2710/20023 ,  C12N2710/20034 ,  C12N2795/18123

Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.

公开(公告)号：US20170189503A1

公开(公告)日：2017-07-06

申请号：US15118143

申请日：2015-02-11

Applicant: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES ,  STC.UNM

Inventor： Alan Remaley ,  John T. Schillerr ,  Marcelo Amar ,  Bryce Chackerian

IPC: A61K39/00 ,  A61K45/06 ,  C12N9/64

CPC classification number: A61K39/0005 ,  A61K38/10 ,  A61K45/06 ,  A61K47/6901 ,  A61K2039/60 ,  A61K2039/627 ,  A61P9/10 ,  C07K11/00 ,  C07K14/47 ,  C12N9/6454 ,  C12N2795/18123 ,  C12N2795/18134 ,  C12N2795/18141 ,  C12Y304/21061

Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.

公开(公告)号：US09480653B2

公开(公告)日：2016-11-01

申请号：US14627739

申请日：2015-02-20

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  Carlee Erin Ashley ,  Xingmao Jiang ,  Juewen Liu ,  David S. Peabody ,  Walker Richard Wharton ,  Eric Carnes ,  Bryce Chackerian ,  Cheryl L. Willman

IPC: A61K9/56 ,  A61K9/127 ,  A61K9/51 ,  A61K49/00 ,  A61K31/575 ,  A61K31/513 ,  A61K33/24 ,  A61K31/704

CPC classification number: A61K9/127 ,  A61K9/1277 ,  A61K9/5115 ,  A61K9/5123 ,  A61K31/513 ,  A61K31/575 ,  A61K31/704 ,  A61K33/24 ,  A61K49/005

Abstract: Various embodiments provide materials and methods for synthesizing protocells for use in targeted delivery of cargo components to cancer cells. In one embodiment, the lipid bilayer can be fused to the porous particle core to form a protocell. The lipid bilayer can be modified with targeting ligands or other ligands to achieve targeted delivery of cargo components that are loaded within the protocell to a target cell, e.g., a type of cancer. Shielding materials can be conjugated to the surface of the lipid bilayer to reduce undesired non-specific binding.

公开(公告)号：US20150320681A1

公开(公告)日：2015-11-12

申请号：US14797487

申请日：2015-07-13

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  Carlee Erin Ashley ,  Xingmao Jiang ,  Juewen Liu ,  David S. Peabody ,  Walker Richard Wharton ,  Eric Carnes ,  Bryce Chackerian ,  Cheryl L. Willman

IPC: A61K9/127 ,  A61K33/24 ,  A61K31/704 ,  A61K31/513 ,  A61K49/00 ,  A61K31/575

CPC classification number: A61K9/127 ,  A61K9/1277 ,  A61K9/5115 ,  A61K9/5123 ,  A61K31/513 ,  A61K31/575 ,  A61K31/704 ,  A61K33/24 ,  A61K49/005

Abstract: Various embodiments provide materials and methods for synthesizing protocells for use in targeted delivery of cargo components to cancer cells. In one embodiment, the lipid bilayer can be fused to the porous particle core to form a protocell. The lipid bilayer can be modified with targeting ligands or other ligands to achieve targeted delivery of cargo components that are loaded within the protocell to a target cell, e.g., a type of cancer. Shielding materials can be conjugated to the surface of the lipid bilayer to reduce undesired non-specific binding.

公开(公告)号：US10279019B2

公开(公告)日：2019-05-07

申请号：US15118143

申请日：2015-02-11

Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES ,  STC.UNM

Inventor： Alan Remaley ,  John T. Schiller ,  Marcelo Amar ,  Bryce Chackerian

IPC: C07K11/00 ,  A61K38/10 ,  A61K39/00 ,  A61P9/10 ,  C12N9/64 ,  A61K45/06 ,  A61K47/69 ,  C07K14/47

Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.

公开(公告)号：US20190038735A1

公开(公告)日：2019-02-07

申请号：US16074886

申请日：2017-02-01

Applicant: STC.UNM

Inventor： Pamela Hall ,  Bryce Chackerian ,  David S. Peabody ,  Seth Michael Daly ,  Bradley Owen Elmore ,  Kathleen Triplett

IPC: A61K39/085 ,  A61P31/04 ,  A61P37/04

CPC classification number: A61K39/085 ,  A61K2039/52 ,  A61K2039/5258 ,  A61P31/04 ,  A61P37/04 ,  C12N2795/18123

Abstract: The present invention is directed to virus-like particles (VLPs) which are engineered to present epitopes from Staphylococcus aureus (SA), preferably autoinducing peptides (AIPs) which regulate quorum-sensing dependent virulence in this pathogen, or epitopes from SA toxins and leukocidins. These VLPs may be used to provide immunogenic compositions and efficacious vaccines. In a mouse model of SA dermonecrosis, vaccination with AIP-containing VLPs or SA toxin-containing VLPs induces protective immunity to limit the pathogenesis of SA infection and promote bacterial clearance.